New York – October 14, 2016 – Cooley advised the underwriters on Novan’s $51.9 million initial public offering. The company now trades on The NASDAQ Global Market under the symbol “NOVN.”

Novan is a late-stage pharmaceutical company focused on redefining the standard of care in dermatology through the development and commercialization of innovative therapies using its nitric oxide platform.

Piper Jaffray & Co. acted as sole book-running manager for the offering. JMP Securities and Wedbush PacGrow acted as co-managers for the offering.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.